Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bejing Anxinhuaide Biotech Co. Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, PAK, MICHAEL D, who is the busiest examiner for the portfolio with 1 pending action. The prosecution is limited to 1 distinct art unit, suggesting a narrow technical focus for the company's current intellectual property efforts.
With only 1 pending office action, the company's immediate success in the biotechnology sector depends on the outcome of this single case. PAK, MICHAEL D is the only examiner the company is currently working with, and this 1 pending action represents the entirety of their active office action pipeline. The involvement of 1 distinct art unit means that the company only needs to comply with the specific standards of one administrative group. This streamlined profile allows for a focused strategy to address the 1 pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564554 | A SUPER-TRAIL MOLECULE COMPRISING TWO TRAIL TRIMERS | PAK, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564554 | A SUPER-TRAIL MOLECULE COMPRISING TWO TRAIL TRIMERS | PAK, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18564554 | A SUPER-TRAIL MOLECULE COMPRISING TWO TRAIL TRIMERS | PAK, MICHAEL D | 1654 | §102§103§112 | Non-Final OA | — | Pending | Nov 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBejing Anxinhuaide Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael D Pak has the most, with 1 of Bejing Anxinhuaide Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
